Abstract
PARP inhibitors (PARPis) are being used in patients with BRCA1/2 mutations. However, doubly deficient BRCA1 –/–53BP1 –/– cells or tumors become resistant to PARPis. Since 53BP1 or its known downstream effec-tors, PTIP and RIF1 (RAP1-interacting factor 1 homolog), lack enzymatic activities directly implicated in DNA repair, we decided to further explore the 53BP1-dependent pathway. In this study, we uncovered a nuclease, Artemis, as a PTIP-binding protein. Loss of Artemis restores PARPi resistance in BRCA1-deficient cells. Collectively, our data demonstrate that Artemis is the major downstream effector of the 53BP1 pathway, which prevents end resection and promotes nonhomologous end-joining and therefore directly competes with the homologous recombination repair pathway.
Original language | English (US) |
---|---|
Pages (from-to) | 2693-2698 |
Number of pages | 6 |
Journal | Genes and Development |
Volume | 28 |
Issue number | 24 |
DOIs | |
State | Published - Dec 15 2014 |
Keywords
- 53BP1
- Artemis
- BRCA1
- DNA repair
- PARP inhibition
- PTIP
ASJC Scopus subject areas
- Genetics
- Developmental Biology